Recro Pharma Inc. (REPH)

11.84
0.09 0.77
NASDAQ : Health Technology
Prev Close 11.75
Open 11.73
Day Low/High 11.45 / 12.19
52 Wk Low/High 5.53 / 12.67
Volume 670.65K
Avg Volume 191.20K
Exchange NASDAQ
Shares Outstanding 22.43M
Market Cap 262.86M
EPS -3.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Risk of Further Market Downside Is Very High Here

Risk of Further Market Downside Is Very High Here

These buyers are most likely to be flippers and they will exit fast and kill the bounce tries.

Here Are 6 Small-Caps on My Radar

Here Are 6 Small-Caps on My Radar

I'm optimistic that we will see some better stock picking action if the breakout holds and momentum continues.

Recro Pharma Reports Second Quarter 2019 Financial Results

Recro Pharma Reports Second Quarter 2019 Financial Results

Record Results and Raising Guidance Announces Plan to Spin Acute Care Company to Host Conference Call Today at 8:00 AM ET MALVERN, Pa.

Recro Pharma To Report Second Quarter 2019 Financial Results And Host Conference Call And Webcast On August 8, 2019

Recro Pharma To Report Second Quarter 2019 Financial Results And Host Conference Call And Webcast On August 8, 2019

Conference Call and Webcast Scheduled for Thursday, August 8, 2019 at 8:00 a.m. ET

Dealing With Biotech Stocks That Face Setbacks

Dealing With Biotech Stocks That Face Setbacks

Knowing when to continue to fish or cut bait is something that develops over time in this space.

Recro Pharma Reaches Analyst Target Price

Recro Pharma Reaches Analyst Target Price

In recent trading, shares of Recro Pharma, Inc have crossed above the average analyst 12-month target price of $8.12, changing hands for $8.34/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Recro Pharma Is Now Oversold (REPH)

Recro Pharma Is Now Oversold (REPH)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Gold Stocks Are Positive on a Negative Day: Here Are My 2 Favorites

Gold Stocks Are Positive on a Negative Day: Here Are My 2 Favorites

While today's action isn't attractive, we were ripe for a little profit-taking.

Notable Monday Option Activity: REPH, PRI, MRNS

Notable Monday Option Activity: REPH, PRI, MRNS

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Recro Pharma, Inc , where a total of 512 contracts have traded so far, representing approximately 51,200 underlying shares. That amounts to about 45.8% of REPH's average daily trading volume over the past month of 111,890 shares.

Recro Pharma Enters Oversold Territory (REPH)

Recro Pharma Enters Oversold Territory (REPH)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses On Their Investment In Recro Pharma, Inc. Of Class Action Lawsuit And Upcoming Deadline - REPH

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses On Their Investment In Recro Pharma, Inc. Of Class Action Lawsuit And Upcoming Deadline - REPH

Pomerantz LLP announces that a class action lawsuit has been filed against Recro Pharma, Inc.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses On Their Investment In Recro Pharma, Inc. Of Class Action Lawsuit And Upcoming Deadline - REPH

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses On Their Investment In Recro Pharma, Inc. Of Class Action Lawsuit And Upcoming Deadline - REPH

Pomerantz LLP announces that a class action lawsuit has been filed against Recro Pharma, Inc.

REPH TICKER ALERT: Rosen Law Firm Reminds Recro Pharma, Inc. Investors Of Important Deadline In Lawsuit- REPH

REPH TICKER ALERT: Rosen Law Firm Reminds Recro Pharma, Inc. Investors Of Important Deadline In Lawsuit- REPH

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Recro Pharma, Inc.

EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of Recro Pharma, Inc. Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of July 30, 2018

EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of Recro Pharma, Inc. Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of July 30, 2018

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Recro Pharma, Inc.

INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders Of Recro Pharma, Inc. Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of July 30, 2018

INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders Of Recro Pharma, Inc. Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of July 30, 2018

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Recro Pharma, Inc.

The Klein Law Firm Reminds Investors Of An Investigation Concerning Possible Violations Of Federal Securities Laws By Recro Pharma, Inc. (REPH)

The Klein Law Firm Reminds Investors Of An Investigation Concerning Possible Violations Of Federal Securities Laws By Recro Pharma, Inc. (REPH)

The Klein Law Firm announces the commencement of an investigation of Recro Pharma, Inc.

The Klein Law Firm Notifies Investors Of An Investigation Concerning Possible Violations Of Federal Securities Laws By Recro Pharma, Inc. (REPH)

The Klein Law Firm Notifies Investors Of An Investigation Concerning Possible Violations Of Federal Securities Laws By Recro Pharma, Inc. (REPH)

The Klein Law Firm announces the commencement of an investigation of Recro Pharma, Inc.

REPH INVESTOR ALERT: The Law Offices Of Vincent Wong Reminds Investors Of An Investigation Involving Possible Securities Fraud Violations By The Board Of Directors Of Recro Pharma, Inc.

REPH INVESTOR ALERT: The Law Offices Of Vincent Wong Reminds Investors Of An Investigation Involving Possible Securities Fraud Violations By The Board Of Directors Of Recro Pharma, Inc.

The Law Offices of Vincent Wong notifies investors of an investigation concerning whether Recro Pharma, Inc.

REPH SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Notifies Investors Of An Investigation Involving Possible Securities Fraud Violations By The Board Of Directors Of Recro Pharma, Inc.

REPH SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Notifies Investors Of An Investigation Involving Possible Securities Fraud Violations By The Board Of Directors Of Recro Pharma, Inc.

The Law Offices of Vincent Wong notifies investors of an investigation concerning whether Recro Pharma, Inc.

Kaskela Law LLC Files Shareholder Class Action Lawsuit Against Recro Pharma, Inc.

Kaskela Law LLC Files Shareholder Class Action Lawsuit Against Recro Pharma, Inc.

Kaskela Law LLC has filed a shareholder class action lawsuit against Recro Pharma, Inc.

EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Recro Pharma, Inc. - REPH

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Recro Pharma, Inc.

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation Of Recro Pharma, Inc.

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation Of Recro Pharma, Inc.

Kaskela Law LLC is investigating Recro Pharma, Inc. (NASDAQ: REPH) ("Recro" or the "Company") on behalf of the Company's shareholders.

TheStreet Quant Rating: D (Sell)